PolyModels Hub, with a Greek co-founder, has announced a €7.8 million ($9 million) Series A funding round led by Molten Ventures, with participation from Marathon Venture Capital.
👯 Founders: Antonio Benedetti, Charalampos Christodoulou, and Antonio Yankey
📅 Founding year: 2023
🏭 Industry: Biopharmaceutical technology / Drug development software
💥 Problem: Drug development relies heavily on manual, non-standardized wet-lab experimentation and fragmented processes, leading to long timelines, high costs, and delays in bringing new medicines to market.
📣 Solution: A unified digital hub offering modelling, simulation, and workflow management to design, test, and optimize drug development processes using data and automation.
👥 Customers: Four of the world’s top ten pharmaceutical companies; academic labs and industrial R&D teams.
🌱 Stage: Series A
💰 Investment amount: €7.8 million Series A round
🚀 Funded by: Molten Ventures (lead), Marathon Venture Capital (participant)
👁️🗨️ Investor’s perspective:
“We are privileged to be day one partners with this deeply technical, domain-native group of engineers and scientists, with backgrounds at GSK, Eli Lilly, AstraZeneca, Johnson & Johnson, Amazon, and beyond. Currently, the company employs 20, of whom 1 in 4 has a PhD. The team has also developed a community of over 6,000 scientists and engineers by curating and sharing cutting-edge research and scientific insights, making them widely recognized among academic labs and industrial teams,” shared Marathon Venture Capital in their blog.
💡 It will be spent on: Geographical expansion, product development, and scaling the platform across additional functions in the drug development lifecycle.
💪 Their specialty: Advanced modelling, simulation, and workflow automation for drug development; deep scientific and engineering expertise with a team including multiple PhDs and former leaders from major pharma companies.
🔑 Business model: Enterprise SaaS
👩🏫 Market: Global biopharmaceutical R&D and manufacturing, with demand for digitalization, process automation, and more efficient drug development pipelines.
📊 Total funding: €8.98 million
